PDL-1 Antibody Drug Conjugate for Selective Chemo-Guided Immune Modulation of Cancer
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
PDL-1 Antibody Drug Conjugate for Selective Chemo-Guided Immune Modulation of Cancer
Authors
Keywords
-
Journal
Cancers
Volume 11, Issue 2, Pages 232
Publisher
MDPI AG
Online
2019-02-18
DOI
10.3390/cancers11020232
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Multifunctional nanoparticles for cancer immunotherapy: A groundbreaking approach for reprogramming malfunctioned tumor environment
- (2018) Samaresh Sau et al. JOURNAL OF CONTROLLED RELEASE
- CD44 directed nanomicellar payload delivery platform for selective anticancer effect and tumor specific imaging of triple negative breast cancer
- (2018) Zhaoxian Wang et al. Nanomedicine-Nanotechnology Biology and Medicine
- Tumor hypoxia directed multimodal nanotherapy for overcoming drug resistance in renal cell carcinoma and reprogramming macrophages
- (2018) Hashem O. Alsaab et al. BIOMATERIALS
- De-novo and acquired resistance to immune checkpoint targeting
- (2017) Nicholas L Syn et al. LANCET ONCOLOGY
- Combination of cationic dexamethasone derivative and STAT3 inhibitor (WP1066) for aggressive melanoma: a strategy for repurposing a phase I clinical trial drug
- (2017) Samaresh Sau et al. MOLECULAR AND CELLULAR BIOCHEMISTRY
- Cancer: Imaging with antibodies
- (2017) Rosie Mestel NATURE
- Beyond the margins: real-time detection of cancer using targeted fluorophores
- (2017) Ray R. Zhang et al. Nature Reviews Clinical Oncology
- Strategies and challenges for the next generation of antibody–drug conjugates
- (2017) Alain Beck et al. NATURE REVIEWS DRUG DISCOVERY
- Interferon Receptor Signaling Pathways Regulating PD-L1 and PD-L2 Expression
- (2017) Angel Garcia-Diaz et al. Cell Reports
- PD-1 and PD-L1 Checkpoint Signaling Inhibition for Cancer Immunotherapy: Mechanism, Combinations, and Clinical Outcome
- (2017) Hashem O. Alsaab et al. Frontiers in Pharmacology
- Atezolizumab: feasible second-line therapy for patients with non-small cell lung cancer? A review of efficacy, safety and place in therapy
- (2017) Fanny Jean et al. Therapeutic Advances in Medical Oncology
- Antibody drug conjugates: lessons from 20 years of clinical experience
- (2016) A. W. Tolcher ANNALS OF ONCOLOGY
- Antibody-drug conjugates—an emerging class of cancer treatment
- (2016) Nikolaos Diamantis et al. BRITISH JOURNAL OF CANCER
- Green Synthesis and Characterization of Monodispersed Gold Nanoparticles: Toxicity Study, Delivery of Doxorubicin and Its Bio-Distribution in Mouse Model
- (2016) Sudip Mukherjee et al. Journal of Biomedical Nanotechnology
- PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations
- (2016) Weiping Zou et al. Science Translational Medicine
- A humanized antibody for imaging immune checkpoint ligand PD-L1 expression in tumors
- (2016) Samit Chatterjee et al. Oncotarget
- Can Targeting Stroma Pave the Way to Enhanced Antitumor Immunity and Immunotherapy of Solid Tumors?
- (2016) E. Pure et al. Cancer Immunology Research
- Development and Evaluation of a Fluorescent Antibody-Drug Conjugate for Molecular Imaging and Targeted Therapy of Pancreatic Cancer
- (2016) Steve Knutson et al. PLoS One
- NF-κB Regulates PD-1 Expression in Macrophages
- (2015) Alexander P. R. Bally et al. JOURNAL OF IMMUNOLOGY
- The Interplay of Immunotherapy and Chemotherapy: Harnessing Potential Synergies
- (2015) Leisha A. Emens et al. Cancer Immunology Research
- Cationic lipid-conjugated dexamethasone as a selective antitumor agent
- (2014) Samaresh Sau et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer
- (2014) Thomas Powles et al. NATURE
- PD-L1 Expression in Triple-Negative Breast Cancer
- (2014) E. A. Mittendorf et al. Cancer Immunology Research
- Soft tissue and visceral sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
- (2012) ANNALS OF ONCOLOGY
- Doxorubicin pathways
- (2010) Caroline F. Thorn et al. Pharmacogenetics and Genomics
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started